JP7621795B2 - 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み - Google Patents

改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み Download PDF

Info

Publication number
JP7621795B2
JP7621795B2 JP2020521596A JP2020521596A JP7621795B2 JP 7621795 B2 JP7621795 B2 JP 7621795B2 JP 2020521596 A JP2020521596 A JP 2020521596A JP 2020521596 A JP2020521596 A JP 2020521596A JP 7621795 B2 JP7621795 B2 JP 7621795B2
Authority
JP
Japan
Prior art keywords
cells
cell
sequence
locus
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020521596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537528A5 (https=
JP2020537528A (ja
Inventor
ブライアン ビュッセル
フィリップ ドゥシャトー
アレクサンドル ジュイレラット
ローラン ポアロ
ジュリアン ヴァルトン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Original Assignee
Cellectis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/076798 external-priority patent/WO2018073391A1/en
Application filed by Cellectis SA filed Critical Cellectis SA
Publication of JP2020537528A publication Critical patent/JP2020537528A/ja
Publication of JP2020537528A5 publication Critical patent/JP2020537528A5/ja
Priority to JP2023015050A priority Critical patent/JP2023055884A/ja
Application granted granted Critical
Publication of JP7621795B2 publication Critical patent/JP7621795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020521596A 2017-10-19 2018-03-09 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み Active JP7621795B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023015050A JP2023055884A (ja) 2017-10-19 2023-02-03 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2017/076798 WO2018073391A1 (en) 2016-10-19 2017-10-19 Targeted gene insertion for improved immune cells therapy
EPPCT/EP2017/076798 2017-10-19
EP2018053343 2018-02-09
EPPCT/EP2018/053343 2018-02-09
PCT/EP2018/055957 WO2019076486A1 (en) 2017-10-19 2018-03-09 TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023015050A Division JP2023055884A (ja) 2017-10-19 2023-02-03 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み

Publications (3)

Publication Number Publication Date
JP2020537528A JP2020537528A (ja) 2020-12-24
JP2020537528A5 JP2020537528A5 (https=) 2021-04-08
JP7621795B2 true JP7621795B2 (ja) 2025-01-27

Family

ID=66173541

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020521596A Active JP7621795B2 (ja) 2017-10-19 2018-03-09 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み
JP2023015050A Pending JP2023055884A (ja) 2017-10-19 2023-02-03 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023015050A Pending JP2023055884A (ja) 2017-10-19 2023-02-03 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み

Country Status (10)

Country Link
US (2) US12209125B2 (https=)
EP (2) EP3684919A1 (https=)
JP (2) JP7621795B2 (https=)
KR (2) KR20200075851A (https=)
CN (1) CN111511903B (https=)
AU (2) AU2018353112B2 (https=)
CA (1) CA3084476A1 (https=)
IL (1) IL273828B2 (https=)
MX (1) MX2020004444A (https=)
WO (2) WO2019076486A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189360A1 (en) * 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
KR20200075851A (ko) 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
EP3802578A4 (en) 2018-06-01 2022-03-23 Washington University SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY
US12378572B2 (en) * 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CN110055224B (zh) * 2019-04-03 2023-06-30 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
MX2021013359A (es) 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
CA3136742A1 (en) * 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
WO2020261219A1 (en) * 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
EP3992204A4 (en) * 2019-06-28 2023-09-27 CRAGE medical Co., Limited CELL FOR RESISTANCE TO TRANSPLANT REACTION AND METHOD
PH12022550542A1 (en) * 2019-09-05 2023-03-20 Crispr Therapeutics Ag Universal donor cells
CA3150235A1 (en) 2019-09-05 2021-03-11 Alireza Rezania Universal donor cells
US20230127263A1 (en) * 2019-09-20 2023-04-27 The University Of North Carolina At Chapel Hill Modified t cells and methods of preparing the same
KR20220141299A (ko) 2020-01-14 2022-10-19 신테카인, 인크. Il2 오르토로그 및 사용 방법
JP2023529211A (ja) * 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
US20230340067A1 (en) * 2020-06-26 2023-10-26 St. Jude Children's Research Hospital, Inc. Methods of generating an activation inducible expression system in immune cells
WO2022020860A2 (en) * 2020-07-24 2022-01-27 Board Of Regents, The University Of Texas System Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing
EP3943097A1 (en) * 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2022112596A1 (en) 2020-11-30 2022-06-02 Cellectis Sa Use of aminoquinoline compounds for higher gene integration
CN114874983A (zh) * 2020-12-29 2022-08-09 博雅辑因（北京）生物科技有限公司 鉴定t细胞调节基因的方法
WO2022144855A1 (en) 2020-12-31 2022-07-07 Crispr Therapeutics Ag Universal donor cells
US20240197880A1 (en) * 2021-04-30 2024-06-20 Cellectis S.A. New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
EP4365203A4 (en) * 2021-07-01 2025-09-24 Ningbo T Maximum Biopharmaceuticals Co Ltd ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND ITS APPLICATION
CN117940465A (zh) * 2021-08-12 2024-04-26 苏州克睿基因生物科技有限公司 经修饰的细胞、其制备方法及应用
EP4514363A4 (en) * 2022-04-25 2026-04-22 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR PREVENTING T LYMPHOCYTE DEPLETION
CN115820697B (zh) * 2022-09-23 2024-07-30 中国海洋大学 一种免疫细胞及其制备方法和应用
WO2024216346A1 (en) * 2023-04-20 2024-10-24 Peter Maccallum Cancer Institute Compositions and methods for immunotherapy - ii
WO2024258835A1 (en) * 2023-06-16 2024-12-19 The Trustees Of Columbia University In The City Of New York Removal of endogenous tcr chains for enhanced tcr-based immunotherapies
TW202509218A (zh) * 2023-07-12 2025-03-01 亨利傑克森軍方醫學基金會 用於抑制自然殺手細胞之組合物及方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016142532A1 (en) 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
WO2016183041A2 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
JP2017508468A (ja) 2014-03-11 2017-03-30 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
WO2017079673A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1994024277A1 (en) 1993-04-13 1994-10-27 Sloan-Kettering Institute For Cancer Research Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
WO1997033988A1 (en) 1996-03-12 1997-09-18 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
CA2361191A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
US9982251B2 (en) 2003-03-14 2018-05-29 Cellectis S.A. Large volume ex vivo electroporation method
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
WO2012098238A1 (en) * 2011-01-21 2012-07-26 Novimmune S.A. Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
CA3205636A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
WO2013188873A1 (en) * 2012-06-15 2013-12-19 Gencia Corporation Compositions and methods for enhancing immune responses
AU2013329186B2 (en) * 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
WO2014191128A1 (en) * 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
BR112017007003A2 (pt) * 2014-10-07 2017-12-19 Cellectis método para modulação de atividade de células imunes induzidas por car
EP4248744A3 (en) * 2015-04-06 2023-12-27 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
GB2592821B (en) * 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
EP3350315A4 (en) * 2015-09-18 2019-07-17 The Regents of The University of California METHOD FOR THE AUTOCATALYTIC GENOMIC PROCESSING AND NEUTRALIZATION OF AUTO CATALYTIC GENOMIC PROCESSING AND COMPOSITIONS THEREFOR
US11815514B2 (en) 2015-12-04 2023-11-14 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
EP3402495A4 (en) * 2016-01-15 2019-06-19 Etubics Corporation METHOD AND COMPOSITIONS FOR T-CELL IMMUNOTHERAPY
JP2019532640A (ja) * 2016-09-29 2019-11-14 ナントクエスト インコーポレイテッド 免疫原性が低下したｈｌａクラスｉ欠損ｎｋ−９２細胞
CN106636090B (zh) * 2016-10-11 2019-08-09 上海优卡迪生物医药科技有限公司 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
KR20200075851A (ko) 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017508468A (ja) 2014-03-11 2017-03-30 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
WO2016142532A1 (en) 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
WO2016183041A2 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
WO2017079673A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｎａｔｕｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ，２０１７ Ａｕｇ．，Ｖｏｌ．３５，Ｎｏ．８，ｐｐ．７６５－７７２ ａｎｄ ＯＮＬＩＮＥ ＭＥＴＨＯＤＳ

Also Published As

Publication number Publication date
WO2019076486A1 (en) 2019-04-25
EP3673049A1 (en) 2020-07-01
AU2018351689A1 (en) 2020-04-30
IL273828B1 (en) 2024-02-01
CN111511903A (zh) 2020-08-07
WO2019076486A9 (en) 2020-05-28
IL273828B2 (en) 2024-06-01
KR20250007705A (ko) 2025-01-14
RU2020115282A (ru) 2021-11-19
JP2023055884A (ja) 2023-04-18
AU2018353112B2 (en) 2024-11-14
AU2018353112A1 (en) 2020-04-23
WO2019076489A1 (en) 2019-04-25
MX2020004444A (es) 2020-07-22
IL273828A (en) 2020-05-31
JP2020537528A (ja) 2020-12-24
CA3084476A1 (en) 2019-04-25
AU2018351689B2 (en) 2025-01-23
US12221478B2 (en) 2025-02-11
US20200407694A1 (en) 2020-12-31
US20200237823A1 (en) 2020-07-30
KR20200075851A (ko) 2020-06-26
RU2020115282A3 (https=) 2021-11-19
EP3684919A1 (en) 2020-07-29
CN111511903B (zh) 2024-10-11
US12209125B2 (en) 2025-01-28

Similar Documents

Publication Publication Date Title
JP7621795B2 (ja) 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み
JP7274416B2 (ja) 改善された免疫細胞療法のための標的指向遺伝子挿入
US11498971B2 (en) BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
WO2018073391A1 (en) Targeted gene insertion for improved immune cells therapy
US20230248825A1 (en) T-cells expressing immune cell engagers in allogenic settings
WO2019016360A1 (en) MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
AU2020415318A1 (en) New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
US11903968B2 (en) Engineered immune cells resistant to tumor microenvironment
RU2824204C2 (ru) Инсерция таргетного гена для улучшенной клеточной иммунотерапии
JP2024519041A (ja) 固形腫瘍における癌関連線維芽細胞を調節することによるｔ細胞媒介性免疫療法の効力の増強

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200520

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210224

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230203

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230314

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230314

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230315

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230407

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230412

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250115

R150 Certificate of patent or registration of utility model

Ref document number: 7621795

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150